Price
No data yet.
Social Signal Score
Analyst Ratings
39 analystsRevenue
$283.69M+881.22%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John F. Sheridan
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 2,500
- Beta
- 1.59
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.53
Financials
Revenue
$283.69M+881.2%Net Income
$-7.08MEBITDA
$-875.0KFree Cash Flow
$-5.51MEPS (diluted)
$-0.10Shares Outstanding (diluted)
69.65M+2156.5%Operating Expenses
$162.79MCash & Debt
$443.08MReturn of Capital
$0.00Revenue by Segment (annual)
$1.01BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.01B | $-204.71M | $-3.04 |
| 2024 | $940.20M | $-96.03M | $-1.47 |
| 2023 | $747.72M | $-222.61M | $-3.43 |
| 2022 | $801.22M | $-94.59M | $-1.47 |
| 2021 | $702.80M | $15.57M | $0.25 |
| 2020 | $498.83M | $-34.38M | $-0.56 |
| 2019 | $362.31M | $-24.75M | $-0.42 |
| 2018 | $183.87M | $-122.61M | $-2.55 |
| 2017 | $107.60M | $-73.03M | $-12.86 |
| 2016 | $84.25M | $-83.45M | $-27.30 |
| 2015 | $72.85M | $-72.42M | $-25.04 |
| 2014 | $49.72M | $-79.52M | $-34.17 |
| 2013 | $29.01M | $-63.14M | $-27.53 |
| 2012 | $2.47M | $-33.02M | $-26.32 |
Valuation
TNDMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
25-64.29%Social Signal Score
Mentions (11)
- Newsseekingalpha.com·6d ago·Negative
Tandem: Wait Out The 2027 Transition Before Chasing The Turnaround I maintain a Hold rating on Tandem Diabetes Care: near-term underperformance offsets significant potential upside after 2027. TNDM's record Q3 revenue rose 13.8%, but international one-offs masked 9% U.S. growth; unchanged FY26 guidance suggests underlying U.S. weakness. PayGo doubles four-year patient revenue to roughly $17,000, but delayed breakeven, attrition risk, and slow pharmacy adoption temper the thesis.
View source ↗ - Newsbenzinga.com·9d ago·Negative
Tandem Mobi Becomes Only Insulin Pump Offering Both Tubed and Tubeless Wear Options Global insulin delivery and diabetes technology company Tandem Diabetes Care, Inc. (NASDAQ:TNDM) secured U.S. Food and Drug Administration clearance for Tandem Mobi as the world's first and only tubeless automated insulin delivery system offering up to seven days of wear for users.
View source ↗ - Newsmarketbeat.com·16d ago·Positive
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call Tandem Diabetes Care NASDAQ: TNDM reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distribution could weigh on revenue growth next year.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript Tandem Diabetes Care, Inc. (TNDM) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Neutral
Tandem Diabetes Care (TNDM) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Tandem Diabetes Care (TNDM) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newszacks.com·44d ago·Neutral
Is it the Right Time to Hold TNDM Stock in Your Portfolio? Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
View source ↗ - Newszacks.com·66d ago·Neutral
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock? Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
View source ↗ - Newszacks.com·74d ago·Positive
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
View source ↗ - Newsbenzinga.com·93d ago·Positive
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
View source ↗ - Newszacks.com·102d ago·Neutral
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
View source ↗
Earnings
Thu, Feb 18(in 3 months)
Consensus estimate $0.08 per share
Typical surprise +3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.10 vs $-0.25beat
- Thu, Aug 6$-0.31 vs $-0.32beat
- Thu, May 7$-0.30 vs $-0.46beat
- Thu, Feb 19$-0.01 vs $-0.05beat
- Thu, Nov 6$-0.31 vs $-0.31beat
- Wed, Aug 6$-0.48 vs $-0.40miss
Estimates and results for TNDM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNDM officers and directors.
- Bought
- —
- Sold
- $33k
0 trades
1 trade
- Twomey Christopher Jsold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Oct 12, 2026 (13d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 16, 2025 (24d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (23d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 7, 2025 (34d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Sep 11, 2024 (37d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 8, 2022 (16d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
